Cantrixil Receives Orphan Drug Designation from FDA
SYDNEY, April 22, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company withYale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, C...
Novogen Conducts Private Placement and Announces Rights Offering to Shareholders
SYDNEY, April 21, 2015 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ:NVGN) ("Company" or "Novogen"), an Australian/US biotechnology company, advises that it has entered into definitive agreements today to issue approximately 51 million fully-paid ordinary shares plus one attaching 6-month opti...
Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer
NEW YORK, April 21, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of thi...
Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer
SYDNEY, April 17, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen, today announced that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research ('Feinstein Institute') ofNew York to collaborate with the objective of developing effective tre...
Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma
SYDNEY, April 9, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their muta...
Novogen Engages Leading US Investor Relations Firm
SYDNEY, April 2, 2015 /PRNewswire/ -- Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key re...
Yale University and Novogen Release Data on Cantrixil Mode of Action
SYDNEY, March 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN) and its subsidiary, CanTx, Inc., andYale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation ...
Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study
SYDNEY, March 19, 2015 /PRNewswire/ -- Novogen announced on 18th March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell's cytoskeleton can deliver ...
Sky News, Helen Dalley interviews Dr Graham Kelly
SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN')CEO, Dr Graham Kelly, PhD, was interviewed by Sky News', Helen Dalley about the breakthrough brain cancer drug being developed by Novogen. Novogen is an Australian-US drug discovery company focused on the clinical ...
Novogen to Present at AusBiotech "Broker Meets Biotech" Event
SYDNEY, March 3, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN'), an Australian-US drug discovery company focused on the clinical development of drugs targeting two novel drug targets pertinent to a range of therapeutic indications, announced today thatGraham Kelly, PhD, CEO and Exe...
ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer
SYDNEY, Sept. 29, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) CEO & Chairman, DrGraham Kelly, conducted an interview with ABC TV that was broadcast onSaturday September 27th during the national 7.00 pm news bulletin and on the following day on Weekend Breakfast. The interview conce...
